Body Mass Index and Effectiveness of Reperfusion Strategies: Implications for the Management of Patients with ST-Elevation Myocardial Infarction
- 1 February 2008
- journal article
- research article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 21 (1), 8-14
- https://doi.org/10.1111/j.1540-8183.2007.00311.x
Abstract
Fibrinolytic therapy has maximum dose limit in patients with ST-elevation myocardial infarction (STEMI). Consequently, obese patients receive lower dose of fibrinolytic per kg body weight compared to lower weight patients. Whether the relatively lower dose results in lower effectiveness of fibrinolytic agents versus primary percutaneous coronary interventions (PCI) in patients with higher body mass index (BMI) is not known. We analyzed 7,630 STEMI patients receiving primary PCI (46%) or fibrinolysis (54%) < 24 hours of symptom onset from the MITRA PLUS registry. The relative effectiveness of the 2 reperfusion strategies on in-hospital death (adjusted with propensity scores) and bleeding were studied in 3 BMI groups: I-BMI 20-24.9 kg/m(2) (n = 2,277), II-BMI 25-29.9 kg/m(2) (n = 3,763), and III-BMI > or = 30 kg/m(2) (n = 1,590). BMI was inversely related to death, shock, stroke, and bleeding in patients treated with either reperfusion strategy. However, compared with primary PCI, fibrinolysis was associated with higher adjusted death with similar relative adjusted difference in all 3 groups (group I OR 1.69, 95% CI 1.19-2.44; group II OR 1.89, 95% CI 1.39-2.56; group III OR 1.85, 95% CI 1.08-3.22). Compared with primary PCI, fibrinolysis was associated with relatively similar higher risk of death in all 3 BMI groups. Whether the differences in death between fibrinolysis and primary PCI in the high-BMI categories can be reduced by higher fibrinolytic doses without increasing bleeding risks needs evaluation in future studies.Keywords
This publication has 13 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarctionEuropean Heart Journal, 2007
- Prediction of One-Year Mortality Among 30-Day Survivors After Primary Percutaneous Coronary InterventionsThe American Journal of Cardiology, 2006
- Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapiesThe American Journal of Cardiology, 2003
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis: Results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry (MIR)Journal of the American College of Cardiology, 2000
- TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at PresentationCirculation, 2000
- Annual Deaths Attributable to Obesity in the United StatesJAMA, 1999
- Body-Mass Index and Mortality in a Prospective Cohort of U.S. AdultsThe New England Journal of Medicine, 1999
- Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial InfarctionCirculation, 1995